[ Diretor: Mário Frota [ Coordenador Editorial: José Carlos Fernandes Pereira [ Fundado em 30-11-1999 [ Edição III [ Ano XII

segunda-feira, 10 de julho de 2017

Pharma firms and consumer groups united over EMA relocation

The UK currently contributes around 20% of the scientific rapporteurs that basically lead the assessments.
[Scott & White Healthcare/Flickr]

The discussion about the relocation of the EMA has kick-started and EU leaders are expected to make a final decision in November.

More than 20 member states have already expressed their interest in hosting the EU drug agency. Analysts say the talks have inevitably been politicised.

However, the pharmaceutical industry and consumer groups are urging EU leaders to focus on business continuity and avoid potential risks for patients.

Diplomat: UK should not think EU ‘weak’ on drug agency relocation

EU member states are urged to put on a united front on the issue of relocating the London-based European Medicines Agency (EMA), rather than bicker publicly and give the UK government reason to believe the bloc cannot cooperate properly, diplomats have told EURACTIV.com.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has said that the main priority is to put an end to the uncertainty over the location of the EMA, as well as to ensure transitional arrangements are in place for issues that can impact on patient safety and health.


Sem comentários: